Liquid chromatography-mass spectrometry for simultaneous determination of spironolactone and canrenone in plasma samples
DOI:
https://doi.org/10.1590/s2175-97902023e21626Keywords:
Bionalytical method, High-performance liquid chromatography, Pharmacokinetics, AntiandrogenAbstract
In our study, we aimed to validate a method based on liquid chromatography-mass spectrometry (LC-MS) to quantify spironolactone (SPI) and its active metabolite canrenone (CAN) simultaneously in plasma samples to support in vivo experiments. Compounds were separated by using a C18 column with the isocratic elution of a mobile phase composed of 0.1% (v/v) formic acid in methanol-water (60:40 v/v) at a flow rate of 0.4 mL min−1. SPI and CAN were detected in na electrospray interface operating in a positive ionization mode and quantified using the selective ion mode monitoring of mass-charge ratios (m/z) of 439.0 for SPI and 363.1 for CAN. After calculating the matrix effect using theoretical equations, we observed the strong interference of plasma in the equipment-generated signal, which required creating analytical curves using the matrix as a solvent. The method was nevertheless linear (r 2 > 0.999) in a concentration range of 0.4-5.0 μg mL−1, as well as precise, with a coefficient of variation less than 5%. SPI’s and CAN’s recovery rates from the plasma ranged from 87.4% to 112.1%, while their limits of detection (i.e., 0.07 μg mL−1 and 0.03 μg mL−1, respectively) and quantification (i.e., 0.20 μg mL−1 and 0.08 μg mL−1, respectively) in the presence of plasma contaminants were low. Therefore, the bioanalytical method seems to be feasible for quantifying SPI and CAN in plasma.
Downloads
References
Afzali BM, Yaghoobi E, Yaghoobi R, Bagherani N, Dabbagh MA. Comparison of the efficacy of 5% topical spironolactone gel and placebo in the treatment of mild and moderate acne vulgaris: a randomized controlled trial. J Dermatol Treat. 2012;23(1):21-25.
Akbari J, Maniruzzaman M, Valizadeh H, Farmoudeh A, Saeedi M, Nokhodchi A, et al. Development and optimisation of spironolactone nanoparticles for enhanced dissolution rates and stability. AAPS PharmSciTech. 2016;18(5):1469-1474.
Anderson JFF, Gerlin MCG, Sversut RA, Oliveira LCS, Singh AK, Amaral MS, et al. Development and validation of an isocratic HPLC method for simultaneous determination of quaternary mixtures of antihypertensive drugs in pharmaceutical formulations hypertension is a main risk factor for cardiovascular and kidney diseases. Acta Chromatogr. 2017;29(1):95-110.
Ayatollahi A, Samadi A. Efficacy and safety of topical spironolactone 5 % cream in the treatment of acne: a pilot study. Health Sci Rep. 2021;4(3):1-5.
Dong H, Xu F, Zhang Z, Tian Y, Chen Y. Simultaneous determination of spironolactone and its active metabolite canrenone in human plasma by HPLC-APCI-MS. J Mass Spectrom. 2006;41(4):477-486.
Elkordy AA, Tan XN, Essa EA. Spironolactone release from liquisolid formulations prepared with CapryolTM 90, Solutol® HS-15 and Kollicoat® SR 30 D as non-volatile liquid vehicles. Eur J Pharm Biopharm. 2013;83(2):203-223.
FDA, Food and Drug Administration. Bioanalytical method validation guidance, 2018.
Ferreira-Nunes R, Angelo T, Márcia S, Oliveira P, Tais G, Cunha-Filho MSS, et al. Versatile chromatographic method for catechin determination in development of topical formulations containing natural extracts. Biomed Chromatogr. 2017;32(2):1-8.
Ferreira-Nunes R, Ferreira LA, Gratieri T, Cunha-Filho M, Gelfuso GM. Stability-indicating analytical method of quantifying spironolactone and canrenone in dermatological formulations and iontophoretic skin permeation experiments. Biomed Chromatogr . 2019;33(11):0-2.
Ferreira-Nunes R, Cunha-Filho M, Gratieri T, Gelfuso GM. Follicular-targeted delivery of spironolactone provided by polymeric nanoparticles. Colloids Surf B Biointerfaces. 2021;208(December2021):112101.
ICH, International Conference on Harmonization, Topic M10 BIOANALYTICALMETHOD VALIDATION M.10, 2019.
Kaukonen AM, Vuorela P, Vuorela H, Mannermaa JP. High-performance liquid chromatography methods for the separation and quantitation of spironolactone and its degradation products in aqueous formulations and of its metabolites in rat serum. J Chromatogr A. 1998;797(1-2):271-281.
Kaukonen AM, Lennernäs H, Mannermaa JP. Water-soluble β-cyclodextrins in paediatric oral solutions of spironolactone: Preclinical evaluation of spironolactone bioavailability from solutions of β-cyclodextrin derivatives in rats. J Pharm Pharmacol. 1998;50(6):611-619.
Kim GK, Del Rosso JQ. Oral spironolactone in post-teenage female patients with acne vulgaris: practical considerations for the clinician based on current data and clinical experience. J Clin Aesthet Dermatol. 2012;5(3):37-50.
Kosmas CE, Silverio D, Sourlas A, Montan PD, Guzman E. Role of spironolactone in the treatment of heart failure with preserved ejection fraction. Ann Transl Med. 2018;6(23):461-461.
Langguth P, Hanafy A, Frenzel D, Grenier P, Nhamias A, Ohlig T. Nanosuspension formulations for low-soluble drugs: pharmacokinetic evaluation using spironolactone as model compound. Drug Dev Ind Pharm. 2005;31(3):319-329.
Laouini A, Jaafar-Maalej C, Sfar S, Charcosset C, Fessi H. Liposome preparation using a hollow fiber membrane contactor - Application to spironolactone encapsulation. Int J Pharm. 2011;415:53-61.
Li ZH, Deng Y, Cai HL, Guo ZH, Hou ZY, Wu G, et al. Pharmacokinetic properties and bioequivalence of spironolactone tablets in fasting and fed healthy Chinese male subjects. Int J Clin Pharmacol Ther. 2016;54(6):455-461.
Oliveira PM, Sampaio TR, França LCF, Gratieri T, Cunha-Filho M, Gelfuso GM. LC-MS bioanalytical method for simultaneous determination of latanoprost and minoxidil in the skin. J Pharm Biomed Anal. 2020;187:113373.
Pamnani MB, Whitehorn WV, Clough DL, Haddy FJ. Effects of canrenone on blood pressure in rats with reduced renal mass. Am J Hypertens. 1990;3(3):188-195.
Rosa AM, Gerlin MCG, Alcântara IC, Sversut RA, Cardoso TFM, Rodrigues PO, et al. Development and stability study of extemporaneous oral formulations from commercial tablets containing spironolactone. Rev Ciênc Farm Básica Apl. 2014;35(3):385-392.
Rudzki PJ, Gniazdowska E, Buś-kwaśnik K. Quantitative evaluation of the matrix effect in bioanalytical methods based on LC-MS: a comparison of two approaches. J Pharm Biomed Anal . 2018;155:314-319.
Sandall JM, Millership JS, Collier PS, Mcelnay JC. Development and validation of an HPLC method for the determination of spironolactone and its metabolites in paediatric plasma samples. J Chromatogr B. 2006;839(1-2):36-44.
Shamma RN, Aburahma MH. Follicular delivery of spironolactone via nanostructured lipid carriers for management of alopecia. Int J Nanomed. 2014;9:5449-5460.
Shaw JC. Acne: effect of hormones on pathogenesis and management. Am J Clin Dermatol. 2002;3(8):571-578.
Sica DA. Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail Rev. 2005;10(1):23-29.
Takkis K, Aro R, Kõrgvee LT, Varendi H, Lass J, Herodes K, et al. Signal enhancement in the HPLC-ESI-MS/MS analysis of spironolactone and its metabolites using HFIP and NH4F as eluent additives. Anal Bioanal Chem. 2017;409(12):3145-3151.
Vlase L, Imre S, Muntean DL, Muntean D, Achim M. Determination of spironolactone and canrenone in human plasma by high-performance liquid chromatography with mass spectrometry detection. Croat Chem Acta. 2011;84(3):361-366.
Wille K, De Brabander HF, Vanhaecke L, De Wulf E, Van CP, Janssen CR. Coupled chromatographic and mass- spectrometric techniques for the analysis of emerging pollutants in the aquatic environment. TrAC - Trends Anal Chem. 2012;35:87-108.
Wong CS, MacLeod SL. JEM Spotlight: Recent advances in analysis of pharmaceuticals in the aquatic environment. J Environ Monit. 2009;11(5):923-936.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on-line journal has open and free access.
